leisure time -WSS

leisure time

author：leisure time 2025-10-02 00:28:18 - browse：3887

When is a billion-dollar deal a bad omen? Has Wall Street gone overboard on Ozempic? And how do you edit a chicken?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss Bristol Myers Squibb’s multibillion-dollar acquisition of Mirati Therapeutics and what it means for a biotech sector still in a slump. We also explain the latest news in the life sciences, including Wall Street’s freakout over GLP-1, CRISPR’ing animals, and the latest in the NASH saga.

For more on what we cover, here’s the news on Mirati; here’s more on biotech venture capital; here’s the latest on Alnylam Pharmaceuticals; here’s more on NASH; here’s the story on xenotransplantation; here’s more on genome-edited chickens; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Readout LOUD: Venture capital, Gilead, and more M&A

WSS

PBM reform efforts get punted in Congress

PBM reform efforts get punted in Congress

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

A protest over insulin prices is seen as a fight for life

Alabama frozen embryo ruling has major implications for IVF clinics

Surgery pushed Ben Carson to fame

Wikipedia

leisure time

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Community Health Systems hospitals under DOJ investigation

Medicare details structure of new drug price negotiation program

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Virginia high school admissions case could be legal follow

AI gets buy

Trump demands the U.S. pay no more for drugs than other countries … again

340B reform proposal comes out of Senate working group

As demand for Covid shots wanes, Moderna seeks its next success

New documents shed light on MD Anderson Cancer Institute feud

hotspot

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

A new nitrogen execution bill also undermines medical licensing

Readout LOUD: Venture capital, Gilead, and more M&A

Problems with a popular proposal to regulate AI in health care

Cano Health’s bankruptcy is a warning for Medicare Advantage

Alabama IVF ruling threatens families facing fatal genetic disease

hotspot

Wikipedia

knowledge

explore